May 7, 2026 01:00AM
Apr 28, 2026 02:00AM
Apr 28, 2026 02:00AM
Apr 28, 2026 02:00AM
Apr 28, 2026 02:00AM
Feb 19, 2026 01:00AM
Aug 14, 2025 01:00AM Zealand Pharma Announces Financial Results for the First Half of 2025
Jun 2, 2025 01:00AM
May 19, 2025 09:00AM
Feb 20, 2025 04:08AM
Feb 20, 2025 01:00AM
Dec 19, 2024 02:59PM
Dec 19, 2024 02:58PM
Nov 7, 2024 01:00AM Zealand Pharma Announces Financial Results for the First Nine Months of 2024
Oct 8, 2024 07:00PM
Oct 8, 2024 06:45PM
Oct 8, 2024 02:40AM
Aug 15, 2024 01:00AM
Jun 7, 2024 04:38AM
Jun 6, 2024 06:29AM
Jun 6, 2024 06:29AM Zealand Pharma announces that Boehringer Ingelheim will present positive results from Phase 2 trial with survodutide in MASH at EASL
May 31, 2024 10:03AM
May 31, 2024 10:03AM
May 16, 2024 01:00AM
Feb 27, 2024 01:00AM
Feb 26, 2024 02:06AM
Dec 26, 2023 04:03AM
Dec 23, 2023 04:47AM U.S. Food and Drug Administration issues Complete Response Letter for dasiglucagon in congenital hyperinsulinism for up to three weeks of dosing due to inspection findings at third-party manufacturing
Dec 22, 2023 04:30AM
Nov 9, 2023 01:00AM
Oct 5, 2023 05:53AM
Aug 30, 2023 01:33AM
Aug 17, 2023 01:00AM
Jun 30, 2023 01:34PM
Jun 30, 2023 01:32PM Zealand Pharma submits New Drug Application to US FDA for dasiglucagon in congenital hyperinsulinism
Jun 23, 2023 05:15PM
May 11, 2023 01:00AM
May 10, 2023 02:30AM
Mar 2, 2023 04:30AM
Mar 2, 2023 04:30AM
Mar 2, 2023 01:00AM
Mar 2, 2023 01:00AM Zealand Pharma Announces Full Year Results for 2022
Nov 10, 2022 09:00AM
Nov 10, 2022 09:00AM
Sep 30, 2022 06:22AM
Sep 30, 2022 06:15AM
Sep 30, 2022 06:15AM
Sep 19, 2022 02:00AM
Sep 19, 2022 02:00AM Zealand Pharma Presents Data from Phase 3 Trial of Dasiglucagon in Congenital Hyperinsulinism at the 60th Annual ESPE Meeting
Sep 7, 2022 02:00AM

322,233 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All